Search the Newsreel

InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares

Ikarian Capital, LLC and Neil Shahrestani have jointly reported a 4.2% beneficial ownership stake in InMed Pharmaceuticals Inc. (INM), totaling 137,634 common shares. This ownership, held through Ikarian Healthcare Master Fund, L.P. and separately managed accounts, is based on 3,314,063 common shares outstanding as …

Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary

Processa Pharmaceuticals (PCSA) reported a net loss of $(3.27M) and diluted EPS of $(1.19) for the third quarter of 2026, showing an improvement from the previous year, with no product revenue. The company recently acquired Vidya, securing $200M in funding to advance new clinical …

H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress

H.C. Wainwright has reiterated a Buy rating and a $60.00 price target for Pharvaris B.V. (NASDAQ:PHVS) due to positive regulatory updates for its hereditary angioedema treatments. The FDA accepted the New Drug Application for deucrictibant IR capsule with a PDUFA action date of April …

Ikarian Capital (CNTB) discloses 6.9% Connect Biopharma holding on Schedule 13G/A

Ikarian Capital, LLC and Neil Shahrestani have disclosed a 6.9% beneficial ownership in Connect Biopharma Holdings Limited Ordinary Shares through a Schedule 13G/A filing. This ownership amounts to 4,338,534 shares, based on 62,974,309 Ordinary Shares outstanding as of July 31, 2026. The filing indicates …

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’

Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock

Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells 18,258 Shares

Cue Biopharma CEO Shao-Lee Lin sold 18,258 shares of the company's stock for over $522,000 to cover tax withholding obligations from vested equity awards. This sale reduced her ownership by 2.52%, following a previous sale of 40,000 shares for $1.08 million. The company recently …

Cue Biopharma CEO Lin sells shares worth $1.6 million

Cue Biopharma CEO Lin Shao-Lee sold shares worth $1.6 million, primarily to cover tax obligations from vested restricted stock units, not as discretionary sales. Concurrently, Mr. Lin acquired 109,179 shares from vested performance stock units. The company has also appointed a new Chief Medical …

Insider plans 58,258-share stock sale (NASDAQ: CUE) under Rule 144

An insider of Cue Biopharma (NASDAQ: CUE) has filed a Rule 144 notice to sell up to 58,258 shares of common stock. These shares originated from restricted stock units that vested on August 1, 2026. The sale is planned to occur in two tranches …

NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results, Misses Estimates By $0.35 EPS

Ascendis Pharma (NasdaqGS:ASND) Stock Turns Profitable As YORVIPATH Drives Growth

Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS

PMV Pharmaceuticals (NASDAQ:PMVP) Posts Earnings Results, Beats Expectations By $0.05 EPS

PMV Pharmaceuticals (NASDAQ:PMVP) reported a quarterly loss of $0.34 per share, beating analyst expectations by $0.05. Following the announcement, the stock rose 3.7% to $1.26. Analysts maintain a "Moderate Buy" rating with a $4.00 consensus price target, despite Oppenheimer lowering its target to $5.00.

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.98 per share a year ago. These figures are adjusted for non-recurring items. This …

Discipline and Rules-Based Execution in BCRX Response

This article provides an AI-driven analysis for Biocryst Pharmaceuticals Inc. (BCRX), highlighting strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 15.0% gain. It details three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for …

(AUPH) Risk Channels and Responsive Allocation

The article analyzes Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), highlighting a weak near-term sentiment despite potential long-term strength. It details an exceptional 43.3:1 risk-reward setup targeting an 11.7% gain versus 0.3% risk, and provides AI-generated institutional trading strategies for various risk profiles. The analysis includes …

Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock

Jennifer Lee, EVP of Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM), sold approximately $8.9 million worth of common stock after exercising options for about $997,036. The sale was executed under a Rule 10b5-1 trading plan as the stock trades near its 52-week high and is considered overvalued …

Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?

On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global partner Takeda Pharmaceutical Company Limited (NYSE:TAK). The payout followed the first patient dosed in the Phase 3 ELRiSE MDS clinical trial, evaluating elritercept against epoetin alfa for …

Rhythm Pharmaceuticals (RYTM) EVP exercises 56,601 options and sells 75,834 shares

Jennifer Kayden Lee, EVP of Rhythm Pharmaceuticals (RYTM), exercised 56,601 stock options at prices of $24.29 and $6.80, and subsequently sold 75,834 common shares at $117.3818 per share. These transactions, valued at approximately $8.90 million gross proceeds from sales and $997K in exercise costs, …

Tonix Pharmaceuticals Holding Corp. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TNXP) 2026-08-14

Tonix Pharmaceuticals Holding Corp. (TNXP) has released its Q2 2026 earnings call presentation. The company reported an EPS of -$2.47, beating estimates by $0.15, and revenue of $13.54M, surpassing estimates by $5.82M with a 577.88% year-over-year increase. The slide deck provides details related to …

Eton Pharmaceuticals (ETON) Stock Reprices Higher After Profit Inflection

Eton Pharmaceuticals (ETON) stock surged 44.3% to US$58.86 after reporting a significant profit inflection in Q2 2026, with net income reaching US$11.6m and EPS of US$0.42 on US$37.6m revenue. This performance has led to increased revenue guidance for 2026 and supports the company's rare …

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will …

SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ:SPRY) on behalf of investors who purchased shares between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements and concealed material adverse …

Anuh Pharma Clears Board Reappointments, Auditor Mandate and Governance Overhaul

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is investigating Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) for potential federal securities law violations after the company announced disappointing Q2 2026 financial results. Alnylam significantly lowered its full-year 2026 TTR product sales guidance, causing its stock price to drop …

Is UroGen Pharma (URGN) Overvalued As Sales Growth And Patent Clarity Lift Confidence?

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. …

Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than …

Helix BioPharma Reshapes Board to Align with Oncology Growth Strategy

(PHAR) and the Role of Price-Sensitive Allocations

This article provides an AI-driven analysis of Pharming Group N.v. (NASDAQ: PHAR), highlighting a near-term strong sentiment potentially challenging mid- and long-term weakness. It outlines specific institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, to assist investors …

Helix Biopharma Corp. Announces Board Composition Changes

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint, Inc. announced the granting of non-statutory stock options to two new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options allow the purchase of up to 14,600 shares of common stock, with an exercise price of $14.75 per share, …

Vor Biopharma (VOR) sees Venrock-led group report 9.99% ownership stake

A Venrock-led group, including Venrock Healthcare Capital and individuals Nimish Shah and Bong Koh, has reported a beneficial ownership stake of 9.99% in Vor Biopharma Inc. (VOR). This stake comprises 5,676,370 shares of common stock, including Pre-Funded Warrants, as of June 30, 2026. A …

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

Traws Pharma announced its Q2 2026 financial results, highlighting progress in advancing tivoxavir marboxil towards MHRA resubmission in Q3 2026 for its influenza challenge study, despite a U.S. FDA clinical hold. The company also detailed its April 2026 private placement, which secured $10 million …

Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax

Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, exercised 750 Performance Share Units (PSUs) on August 12, 2026, converting them into 750 shares of common stock. To cover tax withholding requirements associated with this vesting, 363 shares were withheld by the company at a price …